Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 07/22 05:35:17 pm
1659.5 GBp   +1.31%
07/22GLAXOSMITHKLINE : half-yearly earnings release
07/20DJBrexit Fears and Weak Pound Weigh on Corporate Europe
07/19 APPLE : GlaxoSmithKline partner for arthritis study
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
09/13/2012 | 02:29pm CEST

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502


Stephen Rea

+44 (0) 20 8047 5502


Sarah Spencer

+44 (0) 20 8047 5502


David Daley

+44 (0) 20 8047 5502


US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664


Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543


Tom Curry

+ 1 215 751 5419


Gary Davies

+ 44 (0) 20 8047 5503


James Dodwell

+ 44 (0) 20 8047 2406


Jeff McLaughlin

+ 1 215 751 7002


Ziba Shamsi

+ 44 (0) 20 8047 3289


GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
07/22 GLAXOSMITHKLINE PAKISTAN : Loss of Shares of GlaxoSmithKline Pakistan Limited
07/22GLAXOSMITHKLINE PLC : half-yearly earnings release
07/20DJBrexit Fears and Weak Pound Weigh on Corporate Europe
07/19 APPLE : GlaxoSmithKline partner for arthritis study
07/18 GLAXOSMITHKLINE : Glaxo's ViiV Sees Positive Results In Phase IIIb Triumeq Study
07/18 GLAXOSMITHKLINE : Glaxo Gets China Approval For Cervarix Cervical Cancer Vaccine
07/18DJGLAXOSMITHKLINE : China's Food and Drug Administration Approves GlaxoSmithKline'..
07/14 GLAXOSMITHKLINE : *exane bnp raises glaxosmithkline price target to 1530 pence -..
07/14 GLAXOSMITHKLINE : *jefferies raises glaxosmithkline to 'buy' (hold) - price targ..
07/13DJBusiness Watch -- WSJ
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 SetPoint Off To A Good Start In The Clinic
07/21 Big Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In J..
07/20 A Much-Needed Long Awaited Game Changing Vaccine
07/20 Celgene Pays Through The Nose For A Hand In Immune Checkpoints
07/19 Understanding 'Crisis' And Opportunity - With 3 Choices In The 'Auld Sod'
Financials ( GBP)
Sales 2016 26 340 M
EBIT 2016 6 684 M
Net income 2016 2 803 M
Debt 2016 12 843 M
Yield 2016 4,88%
P/E ratio 2016 32,29
P/E ratio 2017 23,56
EV / Sales 2016 3,56x
EV / Sales 2017 3,42x
Capitalization 80 857 M
More Financials
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 27
Average target price 16,3  GBP
Spread / Average Target -1,5%
Consensus details
EPS Revisions
More Estimates Revisions
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Moncef Slaoui Executive Director & Chairman-Global Vaccines
Roy Malcolm Anderson Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
More Results